At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 19, 2026 at 16:01 ET
Relmada Therapeutics reported financial results for 2025 and provided a corporate update highlighting positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), showing a 76% durable complete response rate and favorable safety. The company secured $160 million in PIPE financing in March 2026, boosting its cash runway through 2029 to fund the upcoming Phase 3 RESCUE program. Despite a reduced net loss, the company remains pre-revenue with no near-term earnings inflection.
- NDV-01 Phase 2 data shows 76% complete response (CR) rate at 12 months and 95% CR at any time in high-risk NMIBC; 80% CR at 12 months in BCG-unresponsive patients
- No Grade ≥3 treatment-related adverse events or treatment discontinuations observed
- FDA alignment confirmed on two registrational pathways for NDV-01: adjuvant intermediate-risk NMIBC and 2L BCG-unresponsive NMIBC
- Oversubscribed $160 million PIPE financing completed in March 2026, led by top healthcare investors
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access